| Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes |
|
Hematology/oncology and stem cell therapy |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Parsing the Paradox of Myelodysplastic Syndromes |
|
Journal of clinical oncology: official journal of the American Society Clinical Oncologysd |
Myelodysplastic Syndromes (MDS) |
| Patient stratification in myelodysplastic syndromes: how a puzzle may become a map |
|
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
| Existing agents, novel agents, or transplantation for high-risk MDS |
|
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
| Outpatient transfusions for myelodysplastic syndromes |
|
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
| Therapy for lower-risk MDS |
|
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
| Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents |
|
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
| Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading? |
|
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS) |
| Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
|
Annals of Oncology: Official Journal of the European Society for Medical Oncology |
Myelodysplastic Syndromes (MDS) |
